DC
Dishman Carbogen Amcis Ltd (DCAL)
₹154.18
Mkt cap
₹2,673 Cr
P/E ratio
147.00
P/B
0.36
Div yield
0.00%
ROE
1.58%
ROCE
3.14%
EPS (TTM)
₹1.05
Book value
₹426
52W range
129–306
Sector
Healthcare
Price history
Previous close
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries. [1]
NSE DCALBSE 540701
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−49.61% from high₹154
₹129+19.98% from low₹306
Current
₹154.18
Prev close
₹152.20
Day
+1.30%
Price performance
1D
+1.30%
1W
−6.14%
1M
−12.89%
3M
−21.99%
6M
+4.53%
1Y
−45.18%
YTD
−39.49%
Financials
Revenue, profit & margin
P/E ratio
147.0×
DCAL is 325% above the sector median of 34.6×
DCAL147.0×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 723 | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 | 720 | 851 | 678 | |
| Expenses | 602 | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 | 607 | 688 | 618 | |
| Operating Profit | 122 | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 | 113 | 163 | 60 | |
| OPM % | 17% | 10% | 6% | 10% | 6% | 19% | 21% | 21% | 20% | 23% | 16% | 19% | 9% | |
| Other Income | 7 | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 | 8 | 7 | 15 | 16 | |
| Interest | 28 | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 | 46 | 43 | 37 | |
| Depreciation | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 | 84 | 89 | 91 | |
| Profit before tax | 29 | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 | 31 | -10 | 46 | -51 | |
| Tax % | 42% | 13% | -10% | 42% | 0% | 21% | 83% | -56% | 39% | -114% | 24% | 53% | 13% | |
| Net Profit | 17 | -41 | -60 | -70 | -78 | 33 | 5 | 43 | 23 | 65 | -13 | 22 | -58 | |
| EPS in Rs | 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 | 4.16 | -0.83 | 1.39 | -3.69 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −7.78% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 14 Aug '26◦ |
| Earnings day | −7.78% |
| +1 day | −11.29% |
| +5 days | −9.13% |
| +15 days | −10.03% |
| +30 days | −15.35% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202659.32%Promoter
Promoters59.32%
FIIs6.86%0.59
DIIs2.06%0.43
Public31.76%0.16
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Dishman Carbogen | ₹170.52 | 147.38 | 2,673 | 0.00% | −58 | −327.64% | 678 | −4.29% | 3.14% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports10
Concall transcripts75
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025PPTSep 2025RECSep 2025TranscriptSep 2025PPTSep 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Disclosure Pursuant To Regulations 30 And 51 Of SEBI (LODR) Regulations, 2015: The Company'S Wholly Owned Subsidiary, CARBOGEN AMCIS AG Successfully Completed US FDA Inspection At Its Manufacturing Site Located At Vionnaz, Switzerland Without Any Observations 12 Sep - CARBOGEN AMCIS AG’s Vionnaz, Switzerland site cleared first US FDA inspection on 11 September 2026 without Form 483.ANNUAL GENERAL MEETING AND E-VOTING NOTICE - NEWS PAPER ADVERTISEMENT 7 Sep - Newspaper advertisement for 19th AGM and e-voting notice; AGM scheduled on 30 September 2026.SUBMISSION OF NOTICE OF 19TH ANNUAL GENERAL MEETING ALONGWITH ANNUAL REPORT FOR THE FINANCIAL YEAR 2025-26 AS PER REGULATIONS 34 AND 53 OF SEBI (LODR) REGULATIONS, 2015 5 Sep - 19th AGM on 30 September 2026 via VC/OAVM; annual report for FY2025-26 submitted.Business Responsibility and Sustainability Reporting (BRSR) 5 Sep - Dishman Carbogen Amcis filed FY2025-26 BRSR with ESG, compliance, workforce and sustainability disclosures.Reg. 34 (1) Annual Report. 5 Sep